Suppr超能文献

急诊科及其他医疗机构的医生在开具丁丙诺啡治疗阿片类物质使用障碍方面的障碍与促进因素

Barriers and facilitators to prescribing buprenorphine for treating opioid use disorder among emergency department and other practice setting physicians.

作者信息

Swartz James A, Franceschini Dana, Marino Nora M, Call Adrienne H, Rosenberger Lisa, Whitehouse Sarah

机构信息

Jane Addams College of Social Work, University of Illinois Chicago, 1040 W. Harrison St., MC (309), Chicago IL 60607, USA.

National Opinion Research Center at the University of Chicago, 55 East Monroe St, 30th Floor, Chicago IL 60603, USA.

出版信息

AIMS Public Health. 2025 Jan 9;12(1):56-76. doi: 10.3934/publichealth.2025005. eCollection 2025.

Abstract

Despite federal legislation intended to increase the prescribing of buprenorphine as medication for opioid use disorder (MOUD), such as the Drug Addiction Treatment Act (DATA) of 2000, most providers have continued to prescribe to some patients or to not prescribe at all. We aimed to determine the continuing barriers and supports needed for expanding buprenorphine prescribing and compared barriers experienced by emergency department (ED) physicians with those in other practice settings, given the unique aspects of the ED practice setting. We obtained survey data from August through November 2021 from 412 X-waivered Illinois physicians licensed to prescribe buprenorphine as MOUD, 95 (23.1%) of whom worked primarily in a hospital-based ED. Survey questions included: 1) Professional background, practice characteristics, and prescribing practices; 2) barriers to prescribing buprenorphine; 3) barriers to expanding prescribing; and 4) training/additional supports needed to facilitate buprenorphine prescribing. We used bivariate crosstabulations and multivariable OLS and binary logistic regressions to compare the responses of physicians practicing in the ED versus other practice settings and to compare physicians who prescribed buprenorphine in the past year with those who had not. There were few statistically significant differences among the examined subgroups indicating general agreement regardless of practice setting and prescribing status. The most frequently perceived barrier was having an inadequate community-based behavioral health treatment system to which OUD patients could be referred. Insurance reimbursement, difficulties building practice- and community-based systems to support buprenorphine prescribing, and challenges knowing where and how to refer patients for follow-up and ongoing support services were also prominent concerns. Based on study findings, efforts to expand buprenorphine for OUD might focus on providing support to make and manage treatment referrals and expanding the availability of community-based behavioral healthcare services. Building networks of care could potentially have a greater impact on MOUD availability than increasing the number of practitioners trained to prescribe buprenorphine.

摘要

尽管有旨在增加丁丙诺啡作为阿片类药物使用障碍(MOUD)药物处方的联邦立法,如2000年的《药物成瘾治疗法案》(DATA),但大多数医疗服务提供者仍继续给一些患者开处方,或者根本不开处方。鉴于急诊科(ED)的独特情况,我们旨在确定扩大丁丙诺啡处方所需的持续障碍和支持,并比较急诊科医生与其他执业环境中的医生所面临的障碍。我们获取了2021年8月至11月期间412名获得X豁免的伊利诺伊州医生的调查数据,这些医生被许可开丁丙诺啡作为MOUD药物,其中95名(23.1%)主要在医院急诊科工作。调查问题包括:1)专业背景、执业特点和处方习惯;2)开丁丙诺啡的障碍;3)扩大处方的障碍;4)促进丁丙诺啡处方所需的培训/额外支持。我们使用双变量交叉表、多变量OLS和二元逻辑回归来比较急诊科执业医生与其他执业环境医生的回答,并比较过去一年开丁丙诺啡的医生与未开丁丙诺啡的医生的回答。在所检查的亚组之间几乎没有统计学上的显著差异,这表明无论执业环境和处方状态如何,普遍达成了共识。最常被提及的障碍是缺乏一个完善的社区行为健康治疗系统,无法将患有阿片类药物使用障碍的患者转诊至此。保险报销、建立支持丁丙诺啡处方的执业和社区系统的困难,以及在了解将患者转诊至何处以及如何获得后续和持续支持服务方面的挑战,也是突出的问题。基于研究结果,扩大丁丙诺啡用于治疗阿片类药物使用障碍的努力可能集中在提供支持以进行和管理治疗转诊,以及扩大社区行为医疗服务的可及性。建立护理网络可能比增加接受丁丙诺啡处方培训的从业者数量对MOUD的可及性产生更大影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06e6/11999815/f32a8114c726/publichealth-12-01-005-g001.jpg

相似文献

5
7
Buprenorphine Waiver Attitudes Among Primary Care Providers.
J Prim Care Community Health. 2022 Jan-Dec;13:21501319221112272. doi: 10.1177/21501319221112272.
10
Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings.
J Am Assoc Nurse Pract. 2023 Feb 1;35(2):112-121. doi: 10.1097/JXX.0000000000000811.

本文引用的文献

2
Emergency Department Access to Buprenorphine for Opioid Use Disorder.
JAMA Netw Open. 2024 Jan 2;7(1):e2353771. doi: 10.1001/jamanetworkopen.2023.53771.
3
The End of the X-waiver: Excitement, Apprehension, and Opportunity.
J Am Board Fam Med. 2023 Oct 11;36(5):867-872. doi: 10.3122/jabfm.2023.230048R1. Epub 2023 Sep 13.
5
Use of Medication for Opioid Use Disorder Among Adults With Past-Year Opioid Use Disorder in the US, 2021.
JAMA Netw Open. 2023 Aug 1;6(8):e2327488. doi: 10.1001/jamanetworkopen.2023.27488.
7
Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016-2021.
Drug Alcohol Depend. 2023 Jul 1;248:109933. doi: 10.1016/j.drugalcdep.2023.109933. Epub 2023 May 18.
8
State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements.
Drug Alcohol Depend Rep. 2023 May 2;7:100164. doi: 10.1016/j.dadr.2023.100164. eCollection 2023 Jun.
10
The impact of the mainstreaming addiction treatment act and associated legislative action on pharmacy practice.
J Am Pharm Assoc (2003). 2023 Jul-Aug;63(4):1039-1043. doi: 10.1016/j.japh.2023.04.016. Epub 2023 Apr 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验